Navigation Links
ThermoGenesis Reports First Quarter 2009 Results
Date:11/6/2008

rsus $5.5 million in the same period a year ago.

"Our revenues reflect increased sales of and improved pricing for our BioArchive(R) System and AXP(TM) AutoXpress Platform (AXP(TM)) devices and disposable bag sets. In addition, we were able to reduce our operating expense by almost $1 million versus the fourth quarter of last year as we implemented programs designed to achieve profitability during the current fiscal year," said Dr. William Osgood, Chief Executive Officer.

Osgood said that sales of AXP bag sets during the first quarter of fiscal 2009 were impacted by short-term delays in shipments of AXP devices due to a flawed supplier component, and because the Company filled nearly its entire AXP bag set backlog during the prior quarter.

"We continue to be excited about the distribution agreement with Celling Technologies, a subsidiary of Spine-Smith, LLC, for our MarrowXpress(TM) (MXP(TM)) that we announced last quarter. Celling will be using the MXP for bone marrow stem cell processing in orthopedic surgeries. We expect to see initial revenues during the current quarter from this agreement," Osgood noted.

With respect to fiscal 2009, the Company said it now expects overall revenue growth to be 10-20 percent versus fiscal 2008. This compares to prior guidance for revenue growth of 30-35 percent, reflecting a refined strategy for the Company's Vantus subsidiary that will now focus initially on the Company's Res-Q(TM), a point-of-care solution for bone marrow processing and concentrating platelets from peripheral blood. The Company continues to expect gross margin improvement during the year with fourth quarter 2009 gross margin expected to exceed 40 percent. The company said that it expects to be profitable in the fourth quarter, based on its ability to add new AXP customers, initiate a successful market launch of MXP and Res-Q, and continue aggressive management of expenses in proportion with expected decreases in forecasted revenue. <
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
2. ThermoGenesis Corp. Reports First Quarter 2008 Results
3. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
4. ThermoGenesis Announces Filing of 510(k) Application for MarrowXpress
5. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
6. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
7. Haemacure Reports Third Quarter 2007 Results
8. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. MDS Reports Third Quarter 2007 Results
11. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:REES Announces New Baltimore Office 2Health News:White Pine Systems and Pediatric Web Announce Partnership to Deliver Interoperable and Brandable PHR Solution for Pediatric and Family Practices 2Health News:White Pine Systems and Pediatric Web Announce Partnership to Deliver Interoperable and Brandable PHR Solution for Pediatric and Family Practices 3Health News:White Pine Systems and Pediatric Web Announce Partnership to Deliver Interoperable and Brandable PHR Solution for Pediatric and Family Practices 4Health News:NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3
Other Medicine News:Health News:Avocados may help prevent oral cancer, OSU study shows 2Health News:Ovation further advances development pipeline with new phase III epilepsy study 2Health News:Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach 2Health News:Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows 2Health News:Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows 3Health News:Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows 4Health News:Biotech Finishes on a High in August, Burrill Report Says 2Health News:Biotech Finishes on a High in August, Burrill Report Says 3Health News:Biotech Finishes on a High in August, Burrill Report Says 4Health News:Biotech Finishes on a High in August, Burrill Report Says 5Health News:UPMC Health Plan Launches New Personal Health Record 2Health News:UPMC Health Plan Launches New Personal Health Record 3
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4Prize4Life and the Alzheimer Research Forum Announce Launch of New Web Portal for ALS Research 47980 1Prize4Life and the Alzheimer Research Forum Announce Launch of New Web Portal for ALS Research 47980 2Prize4Life and the Alzheimer Research Forum Announce Launch of New Web Portal for ALS Research 47980 3MassMutual Survey 3A Female Cancer Survivors Better Prepared Financially Than Other Women For Lifes Unexpected Events 47976 1MassMutual Survey 3A Female Cancer Survivors Better Prepared Financially Than Other Women For Lifes Unexpected Events 47976 2MassMutual Survey 3A Female Cancer Survivors Better Prepared Financially Than Other Women For Lifes Unexpected Events 47976 3MassMutual Survey 3A Female Cancer Survivors Better Prepared Financially Than Other Women For Lifes Unexpected Events 47976 4MassMutual Survey 3A Female Cancer Survivors Better Prepared Financially Than Other Women For Lifes Unexpected Events 47976 5Association found between Parkinsons disease and pesticide exposure in French farm workers 47972 1Association found between Parkinsons disease and pesticide exposure in French farm workers 47972 2
Other Medicine Technology:New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 2New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 3New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 4New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 5New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures 6Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 2Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 3Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 4Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 5Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 6Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 7Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 8Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 9Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 10Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 11Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 12Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 13